Perrigo Company plc $PRGO Shares Purchased by Boyar Asset Management Inc.

Boyar Asset Management Inc. boosted its stake in shares of Perrigo Company plc (NYSE:PRGO) by 2.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 26,914 shares of the company’s stock after buying an additional 728 shares during the period. Boyar Asset Management Inc.’s holdings in Perrigo were worth $719,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Janney Montgomery Scott LLC grew its holdings in shares of Perrigo by 18.3% in the second quarter. Janney Montgomery Scott LLC now owns 85,339 shares of the company’s stock valued at $2,280,000 after purchasing an additional 13,213 shares during the period. Sound Income Strategies LLC increased its holdings in shares of Perrigo by 6.2% during the 2nd quarter. Sound Income Strategies LLC now owns 528,964 shares of the company’s stock worth $14,134,000 after buying an additional 30,888 shares during the last quarter. Paragon Capital Management Ltd raised its position in shares of Perrigo by 8.9% during the 2nd quarter. Paragon Capital Management Ltd now owns 7,923 shares of the company’s stock valued at $212,000 after buying an additional 650 shares during the period. Novem Group lifted its holdings in Perrigo by 2.5% in the second quarter. Novem Group now owns 110,770 shares of the company’s stock valued at $2,960,000 after acquiring an additional 2,692 shares during the last quarter. Finally, Public Employees Retirement System of Ohio grew its position in Perrigo by 1.4% in the second quarter. Public Employees Retirement System of Ohio now owns 42,290 shares of the company’s stock worth $1,130,000 after acquiring an additional 564 shares during the period. 95.91% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Geoffrey M. Parker purchased 4,375 shares of the business’s stock in a transaction on Monday, August 18th. The shares were bought at an average price of $22.97 per share, for a total transaction of $100,493.75. Following the acquisition, the director directly owned 33,287 shares in the company, valued at $764,602.39. This trade represents a 15.13% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Eduardo Guarita Bezerra acquired 3,000 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was bought at an average price of $22.74 per share, with a total value of $68,220.00. Following the purchase, the chief financial officer directly owned 48,949 shares in the company, valued at approximately $1,113,100.26. This trade represents a 6.53% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 10,118 shares of company stock valued at $232,699. Company insiders own 0.70% of the company’s stock.

Perrigo Trading Up 1.7%

NYSE PRGO opened at $22.52 on Friday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.24 and a current ratio of 2.32. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of -38.83 and a beta of 0.43. The firm has a 50 day simple moving average of $23.26 and a 200-day simple moving average of $25.42. Perrigo Company plc has a one year low of $20.51 and a one year high of $30.93.

Perrigo (NYSE:PRGO) last announced its earnings results on Wednesday, August 6th. The company reported $0.57 earnings per share for the quarter, missing the consensus estimate of $0.59 by ($0.02). Perrigo had a positive return on equity of 9.09% and a negative net margin of 1.86%.The business had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same period in the previous year, the company earned $0.53 earnings per share. Perrigo’s quarterly revenue was down .9% on a year-over-year basis. Equities research analysts anticipate that Perrigo Company plc will post 2.56 EPS for the current fiscal year.

Perrigo Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 16th. Investors of record on Friday, August 29th were paid a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a yield of 5.2%. The ex-dividend date of this dividend was Friday, August 29th. Perrigo’s payout ratio is presently -200.00%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on PRGO shares. Canaccord Genuity Group decreased their price target on Perrigo from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Wall Street Zen raised shares of Perrigo from a “hold” rating to a “buy” rating in a research report on Sunday, September 28th. Weiss Ratings reiterated a “sell (d)” rating on shares of Perrigo in a research report on Saturday, September 27th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Perrigo from $38.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday, August 7th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $34.00.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.